Clinical efficacy of tacrolimus in systemic lupus erythematosus with various manifestations:a real-world study  

作　　者：Wei Bai Mengtao Li Shuang Zhou Liying Peng Jiuliang Zhao Xinping Tian Qian Wang Xiaomei Leng Shangzhu Zhang Yanhong Wang Yan Zhao Xiaofeng Zeng 

机构地区：[1]Department of Rheumatology and Clinical Immunology,Chinese Academy of Medical Sciences and Peking Union Medical College,National Clinical Research Center for Dermatologic and Immunologic Diseases(NCRC-DID),Ministry of Science and Technology,State Key Laboratory of Complex Severe and Rare Diseases,Peking Union Medical College Hospital(PUMCH),Key Laboratory of Rheumatology and Clinical Immunology,Ministry of Education,Beijing 100730,China [2]Department of Epidemiology and Bio-statistics(YW),Institute of Basic Medical Science,Chinese Academy of Medical Science and Peking Union Medical College,Beijing 100053,China

出　　处：《Chinese Medical Journal》2022年第18期2245-2247,共3页中华医学杂志（英文版）

基　　金：supported by grants from the Chinese National Key Technology R&D Program,Ministry of Science and Technology(Nos.2021YFC2501301-5,2017YFC0907601-3);Beijing Municipal Science&Technology Commission(No.Z201100005520022,23,25-27);CAMS Innovation Fund for Medical Sciences(CIFMS)(No.2021-I2M-1-005).

摘　　要：To the Editor:Systemic lupus erythematosus(SLE)is an autoimmune disease involving multiple systems.In recent years,the therapeutic treat-to-target(T2T)strategy was recommended for SLE.^([1])The immunosuppressive drugs are the standard of care in SLE treatment.Tacrolimus was one of the calcineurin inhibitors which was recommended in the 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association recommendations for the management of lupus nephritis(LN)^([2]).

关 键 词：LUPUS ERYTHEMATOSUS DRUGS 

分 类 号：R593.241[医药卫生—内科学]